Review Article | Published:

Vascular proliferation and atherosclerosis: New perspectives and therapeutic strategies

Nature Medicine volume 8, pages 12491256 (2002) | Download Citation

Subjects

In atherosclerosis, the vascular smooth muscle cell (VSMC) contributes to vessel wall inflammation and lipoprotein retention, as well as to the formation of the fibrous cap that provides stability to the plaque. The VSMC can undergo a proliferative response that underlies the development of in-stent restenosis, bypass graft occlusion and transplant vasculopathy. Although the benefit/risk of therapeutic inhibition of VSMC proliferation in atherosclerosis is unclear, experimental and human evidence strongly suggests the therapeutic potential of antiproliferative therapy for in-stent restenosis, bypass graft failure and other vascular proliferative disorders.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

References

  1. 1.

    Atherosclerosis—an inflammatory disease. N. Engl. J. Med. 340, 115–126 (1999).

  2. 2.

    , & Inflammation and atherosclerosis. Circulation 105, 1135–1143 (2002).

  3. 3.

    Cell biology of atherosclerosis. Annu. Rev. Physiol. 57, 791–804 (1995).

  4. 4.

    & Atherosclerosis and the arterial smooth muscle cell: Proliferation of smooth muscle is a key event in the genesis of the lesions of atherosclerosis. Science 180, 1332–1339 (1973).

  5. 5.

    , & The good smooth muscle cells in atherosclerosis. Curr. Atheroscler. Rep. 2, 422–429 (2000).

  6. 6.

    , & The intima. Soil for atherosclerosis and restenosis. Circ. Res. 77, 445–465 (1995).

  7. 7.

    Conner Memorial Lecture. Mechanisms leading to myocardial infarction: Insights from studies of vascular biology. Circulation 90, 2126–2146 (1994).

  8. 8.

    & Intimal thickening in developing coronary arteries and its relevance to atherosclerosis involvement. Atherosclerosis 23, 345–355 (1976).

  9. 9.

    & Proliferation and the monoclonal origins of atherosclerotic lesions. Annu. Rev. Med. 49, 437–460 (1998).

  10. 10.

    , , & Cell proliferation in human coronary arteries. Proc. Natl. Acad. Sci. USA 87, 4600–4604 (1990).

  11. 11.

    et al. Proliferation in primary and restenotic coronary atherectomy tissue. Implications for antiproliferative therapy. Circ. Res. 73, 223–231 (1993).

  12. 12.

    , , , & Human atherosclerosis. III. Immunocytochemical analysis of the cell composition of lesions of young adults. Am. J. Pathol. 140, 907–914 (1992).

  13. 13.

    et al. Identification of a potential role for the adventitia in vascular lesion formation after balloon overstretch injury of procine coronary arteries. Circulation 93, 2178–2187 (1996).

  14. 14.

    et al. Embryonic endothelial cells transdifferentiate into mesenchymal cells expressing smooth muscle actins in vivo and in vitro. Circ. Res. 80, 444–451 (1997).

  15. 15.

    et al. Hematopoietic stem cells differentiate into vascular cells that participate in the pathogenesis of atherosclerosis. Nature Med. 8, 403–409 (2002).

  16. 16.

    et al. Origin of neointimal endothelium and alpha-actin-positive smooth muscle cells in transplant arteriosclerosis. J. Clin. Invest. 107, 1411–1422 (2001).

  17. 17.

    , & Neointimal formation by circulating bone marrow cells. Ann. NY Acad. Sci. 947, 18–24 (2001).

  18. 18.

    et al. Host bone-marrow cells are a source of donor intimal smooth-muscle-like cells in murine aortic transplant arteriopathy. Nature Med. 7, 738–741 (2001).

  19. 19.

    , , , & Smooth muscle progenitor cells in human blood. Circulation 106, 1199–1204 (2002).

  20. 20.

    , & Cell cycle progression. New therapeutic target for vascular proliferative disease. Circulation 98, 82–89 (1998).

  21. 21.

    et al. A comparison of balloon-expandable-stent implantation with balloon angioplasty in patients with coronary artery disease. N. Engl. J. Med. 331, 489–495 (1994).

  22. 22.

    et al. Ex vivo gene therapy of human vascular bypass grafts with E2F decoy: The PREVENT single-centre, randomised, controlled trial. Lancet 354, 1493–1498 (1999).

  23. 23.

    & Proliferation of smooth muscle cells after vascular injury is inhibited by an antibody against basic fibroblast growth factor. Proc. Natl. Acad. Sci. USA 88, 3739–3743 (1991).

  24. 24.

    et al. Inhibition of neointimal smooth muscle accumulation after angioplasty by an antibody to PDGF. Science 253, 1129–1132 (1991).

  25. 25.

    , , & Production of transforming growth factor β-1 during repair of arterial injury. J. Clin. Invest. 88, 904–910 (1991).

  26. 26.

    et al. Recombinant platelet-derived growth factor B gene expression in porcine arteries induce intimal hyperplasia in vivo. J. Clin. Invest. 91, 1822–1829 (1993).

  27. 27.

    et al. Localization of insulin-like growth factor I and inhibition of coronary smooth muscle cell growth by somatostatin analogues in human coronary smooth muscle cells. A potential treatment for restenosis? Circulation 89, 1511–1517 (1994).

  28. 28.

    , & Molecular mechanisms of vascular renin-angiotensin system in myointimal hyperplasia. Hypertension 18, II100–11105 (1991).

  29. 29.

    , , , & Endothelium-derived relaxing factor produced and released from artery and vein is nitric oxide. Proc. Natl. Acad. Sci. USA 84, 9265–9269 (1987).

  30. 30.

    & Modulation of sulfated proteoglycan synthesis by bovine aortic endothelial cells during migration. J. Cell. Biol. 102, 678–687 (1986).

  31. 31.

    Cell cycle checkpoints: preventing an identity crisis. Science 274, 1664–1671 (1996).

  32. 32.

    , & How the cyclin became a cyclin: Regulated proteolysis in the cell cycle. Cell 97, 431–434 (1999).

  33. 33.

    Mammalian G1 cyclins and cell cycle progression. Proc. Assoc. Am. Phys. 107, 181–186 (1995).

  34. 34.

    p53, the cellular gatekeeper for growth and division. Cell 88, 323–331 (1997).

  35. 35.

    et al. p21CIP1-mediated inhibition of cell proliferation by overexpression of the gax homeodomain gene. Genes Dev. 11, 1674–1689 (1997).

  36. 36.

    , , , & The gene for transcription factor GATA-6 resides on mouse chromosome 18 and is expressed in myocardium and vascular smooth muscle. Genomics 36, 345–348 (1996).

  37. 37.

    , , , & GATA-6 induces p21(Cip1) expression and G1 cell cycle arrest. J. Biol. Chem. 273, 13713–13718 (1998).

  38. 38.

    , & Nitric oxide-induced downregulation of Cdk2 activity and cyclin A gene transcription in vascular smooth muscle cells. Circulation 97, 2066–2072 (1998).

  39. 39.

    , , , & Induction of the cyclin-dependent kinase inhibitor p21(Sdi1/Cip1/Waf1) by nitric oxide-generating vasodilator in vascular smooth muscle cells. J. Biol. Chem. 272, 10050–10057 (1997).

  40. 40.

    & The expanding role of cell cycle regulators. Science 280, 1035–1036 (1998).

  41. 41.

    , , , & Modulation of apoptosis by the cyclin-dependent kinase inhibitor p27(Kip1). J. Clin. Invest. 103, 597–604 (1999).

  42. 42.

    , , & Inhibitory effects of antisense oligodeoxynucleotides targeting c-myc mRNA on smooth muscle cell proliferation and migration. Proc. Natl. Acad. Sci. USA 90, 654–658 (1993).

  43. 43.

    et al. Inhibition of smooth muscle cell migration by the p21 cyclin-dependent kinase inhibitor (Cip1). Atherosclerosis 132, 53–59 (1997).

  44. 44.

    et al. Transcatheter delivery of c-myc antisense oligomers reduces neointimal formation in a porcine model of coronary artery balloon injury. Circulation 90, 944–951 (1994).

  45. 45.

    , , , & A novel role for the cyclin-dependent kinase inhibitor p27KIP1 in angiotensin II-stimulated vascular smooth muscle cell hypertrophy. J. Clin. Invest. 104, 815–823 (1999).

  46. 46.

    et al. Cell cycle inhibition preserves endothelial function in genetically engineered rabbit vein grafts. J. Clin. Invest. 99, 1295–1301 (1997).

  47. 47.

    et al. Regulation of NF-κB by cyclin-dependent kinases associated with the p300 coactivator. Science 275, 523–527 (1997).

  48. 48.

    , , , & Cell cycle-dependent expression of cyclooxygenase-2 in human fibroblasts. Faseb J. 15, 288–290 (2001).

  49. 49.

    et al. Intracellular action of the cytokine MIF to modulate AP-1 activity and the cell cycle through Jab1. Nature 408, 211–216 (2000).

  50. 50.

    et al. Gene therapy inhibiting neointimal vascular lesion: in vivo transfer of endothelial cell nitric oxide synthase gene. Proc. Natl. Acad. Sci. USA 92, 1137–1141 (1995).

  51. 51.

    , , , & Nitric oxide synthase gene therapy rapidly reduces adhesion molecule expression and inflammatory cell infiltration in carotid arteries of cholesterol-fed rabbits. Circulation 99, 2979–2982 (1999).

  52. 52.

    Treating atherosclerosis: Local drug delivery from laboratory studies to clinical trials. Atherosclerosis 160, 259–271 (2002).

  53. 53.

    , & Rapamycin (AY-22,989), a new antifungal antibiotic. II. Fermentation, isolation and characterization. J. Antibiot. (Tokyo) 28, 727–732 (1975).

  54. 54.

    , , & Rapamycin inhibits arterial intimal thickening caused by both alloimmune and mechanical injury. Its effect on cellular, growth factor, and cytokine response in injured vessels. Transplantation 55, 1409–1418 (1993).

  55. 55.

    et al. Cell cycle protein expression in vascular smooth muscle cells in vitro and in vivo is regulated through phosphatidylinositol 3-kinase and mammalian target of rapamycin. Arterioscler. Thromb. Vasc. Biol. 21, 1152–1158 (2001).

  56. 56.

    et al. Inhibition of intimal thickening after balloon angioplasty in porcine coronary arteries by targeting regulators of the cell cycle. Circulation 99, 2164–2170 (1999).

  57. 57.

    , , , & TOR kinase domains are required for two distinct functions, only one of which is inhibited by rapamycin. Cell 82, 121–130 (1995).

  58. 58.

    et al. Rapamycin selectively inhibits interleukin-2 activation of p70 S6 kinase. Nature 358, 70–73 (1992).

  59. 59.

    et al. cAMP- and rapamycin-sensitive regulation of the association of eukaryotic initiation factor 4E and the translational regulator PHAS-I in aortic smooth muscle cells. Proc. Natl. Acad. Sci. USA 92, 7222–7226 (1995).

  60. 60.

    et al. Rapamycin inhibits vascular smooth muscle cell migration. J. Clin. Invest. 98, 2277–2283 (1996).

  61. 61.

    & Role of p70 S6 protein kinase in angiotensin II-induced protein synthesis in vascular smooth muscle cells. J. Biol. Chem. 270, 5225–5231 (1995).

  62. 62.

    et al. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N. Engl. J. Med. 346, 1773–1780 (2002).

  63. 63.

    , , & Mechanism of mitotic block and inhibition of cell proliferation by taxol at low concentrations. Proc. Natl. Acad. Sci. USA 90, 9552–9556 (1993).

  64. 64.

    et al. Paclitaxel inhibits arterial smooth muscle cell proliferation and migration in vitro and in vivo using local drug delivery. Circulation 96, 636–645 (1997).

  65. 65.

    et al. First clinical experience with a paclitaxel derivate-eluting polymer stent system implantation for in-stent restenosis: Immediate and long- term clinical and angiographic outcome. Circulation 105, 1883–1886 (2002).

  66. 66.

    , , & ATP-site directed inhibitors of cyclin-dependent kinases. Curr. Med. Chem. 6, 859–875 (1999).

  67. 67.

    et al. Flavopiridol inhibits smooth muscle cell proliferation in vitro and neointimal formation in vivo after carotid injury in the rat. Circulation 100, 659–665 (1999).

  68. 68.

    et al. CVT-313, a specific and potent inhibitor of CDK2 that prevents neointimal proliferation. J. Biol. Chem. 272, 29207–29211 (1997).

  69. 69.

    et al. Five-year clinical follow-up after intracoronary radiation: results of a randomized clinical trial. Circulation 105, 2737–2740 (2002).

  70. 70.

    et al. Intracoronary gamma-radiation therapy after angioplasty inhibits recurrence in patients with in-stent restenosis. Circulation 101, 2165–2171 (2000).

  71. 71.

    , , , & Human vascular smooth muscle cells from restenosis or in-stent stenosis sites demonstrate enhanced responses to p53: Implications for brachytherapy and drug treatment for restenosis. Circ. Res. 90, 398–404 (2002).

  72. 72.

    et al. Single intraluminal delivery of antisense cdc2 kinase and proliferating-cell nuclear antigen oligonucleotides results in chronic inhibition of neointimal hyperplasia. Proc. Natl. Acad. Sci. USA 90, 8474–8478 (1993).

  73. 73.

    , & Antisense proliferating cell nuclear antigen oligonucleotides inhibit intimal hyperplasia in a rat carotid artery injury model. J. Clin. Invest. 93, 2351–2356 (1994).

  74. 74.

    et al. Local intracoronary administration of antisense oligonucleotide against c-myc for the prevention of in-stent restenosis: results of the randomized investigation by the Thoraxcenter of antisense DNA using local delivery and IVUS after coronary stenting (ITALICS) trial. J. Am. Coll. Cardiol. 39, 281–287 (2002).

  75. 75.

    et al. Chimeric DNA-RNA hammerhead ribozyme to proliferating cell nuclear antigen reduces stent-induced stenosis in a porcine coronary model. Circulation 99, 697–703 (1999).

  76. 76.

    et al. Role of the p21 cyclin-dependent kinase inhibitor in limiting intimal cell proliferation in response to arterial injury. Proc. Natl. Acad. Sci. USA 93, 7905–7910 (1996).

  77. 77.

    , , , & Wild-type p53 gene transfer: a novel therapeutic strategy for neointimal hyperplasia after arterial injury. Ann. NY Acad. Sci. 811, 395–399 (1997).

  78. 78.

    et al. Downregulation of cyclin-dependent kinase 2 activity and cyclin A promoter activity in vascular smooth muscle cells by p27KIP1, an inhibitor of neointima formation in the rat carotid artery. J. Clin. Invest. 99, 2334–2341 (1997).

  79. 79.

    , , , & Reversal of GATA-6 downregulation promotes smooth muscle differentiation and inhibits intimal hyperplasia in balloon-injured rat carotid artery. Circ. Res. 84, 647–654 (1999).

  80. 80.

    et al. Cytostatic gene therapy for vascular proliferative disorders with a constitutively active form of the retinoblastoma gene product. Science 267, 518–522 (1995).

  81. 81.

    & Therapeutic potential of nitric oxide synthase gene manipulation. Circulation 103, 2760–2765 (2001).

  82. 82.

    et al. A gene therapy strategy using a transcription factor decoy of the E2F binding site inhibits smooth muscle proliferation in vivo. Proc. Natl. Acad. Sci. USA 92, 5855–5859 (1995).

  83. 83.

    & Gene therapy for human bypass grafts. Ann. Med. 33, 153–155. (2001).

Download references

Acknowledgements

We thank S.M. Schwartz for suggestions and criticisms in the preparation of this manuscript. V.J.D. is the recipient of a National Heart Lung and Blood Institute MERIT Award. R.C.B.-D. is supported by the Deutsche Forschungsgemeinschaft (Sonderforschungsbereich 547:A7, Graduiertenkolleg 534). D.G.S. is a scholar of the Deutsche Forschungsgemeinschaft (Graduiertenkolleg 534).

Author information

Affiliations

  1. Department of Medicine, Harvard Medical School and Brigham and Women's Hospital, Boston, Massachusetts, USA

    • Victor J. Dzau
  2. Department of Medicine, Giessen University, Giessen, Germany vdzau@partners.org

    • Ruediger C. Braun-Dullaeus
    •  & Daniel G. Sedding

Authors

  1. Search for Victor J. Dzau in:

  2. Search for Ruediger C. Braun-Dullaeus in:

  3. Search for Daniel G. Sedding in:

About this article

Publication history

Published

DOI

https://doi.org/10.1038/nm1102-1249

Further reading